Bedaquiline: A novel antitubercular drug for multidrug-resistant tuberculosis

Journal of Postgraduate Medicine

Volumn 60, Issue 3, 2014, Pages 300-302

  Nagabushan, H ^a   Roopadevi, H ^a  

^a Mandya Rajiv Gandhi University of Medical Sciences   (India)

Author keywords

Adenosine triphosphate synthase enzyme; bedaquiline; multidrug resistant tuberculosis; Mycobacterium tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; BEDAQUILINE; KETOCONAZOLE; LOPINAVIR; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; TERTIARY AMINE; TUBERCULOSTATIC AGENT; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ACNE; AEROBIC METABOLISM; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BACKACHE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESISTANCE; HEARING IMPAIRMENT; HEMOPTYSIS; HUMAN; HYPERTRANSAMINASEMIA; HYPERURICEMIA; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA PROTEIN BINDING; PREGNANCY; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SORE THROAT; VOMITING; DRUG APPROVAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FOOD AND DRUG ADMINISTRATION; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; DRUG APPROVAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84907021518     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.138772     Document Type: Review

References (20)

1. The World Health Organization (WHO) Global Tuberculosis Report 2012. Available from: http://www.who.int/tb/publications/global-report/gtbr12-main.pdf. [Last accessed on 2013 Apr 04].
2. Matteelli A, Carvalho AC, Dooley KE, Kritski A. TMC207: The first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010;5:849-58.
3. Gaurrand S, Desjardins S, Meyer C, Bonnet P, Argoullon JM, Oulyadi H, et al. Conformational analysis of r207910, a new drug candidate for the treatment of tuberculosis, by a combined NMR and molecular modeling approach. ChemBiol Drug Des 2006;68:77-84.
4. Petrella S, Cambau E, Chauffour A, Andries K, Jarlier V, Sougakoff W. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 2006;50:2853-6.
5. Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007;51:4202-4.
6. Koul A, Vranckx L, Dendouga N, Balemans W, Van denWyngaert I, Vergauwen K, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J BiolChem 2008;283:25273-80.
7. Lounis N, Gevers T, Van den Berg J, Vranckx L, Andries K. ATP synthase inhibition of Mycobacterium aviumis not bactericidal.Antimicrob Agents Chemother 2009;53:4927-9.
8. Rustomjee R, Diacon AH, Allen J, Venter A,Reddy C,Patientia RF, et al. Early bactericidal activity and pharmacokinetics of the dairylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831-5.
9. Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, et al. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 2012;56:1444-51.
10. Lenaerts AJ, Hoff D, Aly S, Ehlers S, Andries K, Cantarero L, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 2007;51:3338-45.
11. Andries K, Verhasselt P, Guillemont J,Göhlmann HW, Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-7.
12. Ibrahim M, Andries K, Lounis N,Chauffour A, Truffot-Pernot C, Jarlier V, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007;51:1011-5.
13. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. Mode of action of pyrazinamide: Disruption of Mycobacterium tuberculosismembrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003;52:790-5.
14. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006;50:3543-7.
15. Veziris N, Ibrahim M, Lounis N,Chauffour A, Truffot-Pernot C, Andries K, et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 2009;179:75-9.
16. Lounis N, Gevers T, Van Den Berg J, Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 2008;52:3568-72.
17. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 2009;180:553-7.
18. Gelber R, Andries K, Paredes RM, Andaya CE, Burgos J. The diarylquinoline R207910 is bactericidal against Mycobacterium lepraein mice at low dose and administered intermittently. Antimicrob Agents Chemother 2009;53:3989-91.
19. Diacon AH, Pym A, Grobusch M,Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405.
20. Medication Guideof Bedaquiline Tablet. Available from:http://www.fda.gov/downloads/Drugs/DrugSafety/UCM333729.pdf. [Last accessed on 2013 Apr 05].